McGuire Investment Group LLC Reduces Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

McGuire Investment Group LLC decreased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,394 shares of the medical equipment provider’s stock after selling 231 shares during the quarter. Intuitive Surgical comprises approximately 1.6% of McGuire Investment Group LLC’s portfolio, making the stock its 21st biggest holding. McGuire Investment Group LLC’s holdings in Intuitive Surgical were worth $11,493,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Able Wealth Management LLC purchased a new stake in Intuitive Surgical during the 4th quarter worth about $28,000. GLOBALT Investments LLC GA purchased a new stake in shares of Intuitive Surgical in the fourth quarter worth about $304,000. V Square Quantitative Management LLC boosted its position in shares of Intuitive Surgical by 72.6% in the fourth quarter. V Square Quantitative Management LLC now owns 2,406 shares of the medical equipment provider’s stock valued at $812,000 after acquiring an additional 1,012 shares during the period. Integrated Advisors Network LLC grew its stake in Intuitive Surgical by 6.3% during the fourth quarter. Integrated Advisors Network LLC now owns 1,598 shares of the medical equipment provider’s stock valued at $539,000 after acquiring an additional 95 shares in the last quarter. Finally, Centaurus Financial Inc. increased its holdings in Intuitive Surgical by 12.2% during the 4th quarter. Centaurus Financial Inc. now owns 2,183 shares of the medical equipment provider’s stock worth $737,000 after acquiring an additional 238 shares during the period. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Stock Up 0.2 %

Shares of Intuitive Surgical stock traded up $0.94 during trading on Friday, reaching $484.78. 1,170,154 shares of the stock were exchanged, compared to its average volume of 1,469,034. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $496.48. The firm has a market cap of $172.27 billion, a price-to-earnings ratio of 83.30, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. The stock’s fifty day moving average is $480.34 and its 200 day moving average is $434.94.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The firm had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same period last year, the company earned $1.18 EPS. Equities analysts forecast that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on ISRG shares. Stifel Nicolaus boosted their price target on shares of Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research report on Friday, July 19th. Piper Sandler boosted their target price on Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. BTIG Research lifted their price target on Intuitive Surgical from $469.00 to $494.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Evercore ISI upped their price objective on shares of Intuitive Surgical from $410.00 to $475.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Finally, Royal Bank of Canada boosted their price target on shares of Intuitive Surgical from $515.00 to $525.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus price target of $458.35.

Insider Buying and Selling at Intuitive Surgical

In other news, Director Craig H. Barratt sold 1,400 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $641,382.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Craig H. Barratt sold 1,400 shares of the firm’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $641,382.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Amy L. Ladd sold 450 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the completion of the sale, the director now directly owns 821 shares in the company, valued at approximately $402,519.88. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 53,120 shares of company stock valued at $25,528,753. 0.90% of the stock is currently owned by company insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.